ProCE Banner Activity

CME

Advances in GVHD: Current Treatments, Optimizing Prophylaxis, and Integrating Novel Therapies

Multimedia
Watch this on-demand Webcast capturing a live CCO Webinar to learn the latest evidence for optimizing prophylaxis and treatment of both acute and chronic GVHD.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: December 08, 2020

Expiration: December 07, 2021

No longer available for credit.

Share

Faculty

Corey Cutler

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Nelson Chao

Nelson Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematology Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, North Carolina

David Miklos

David Miklos, MD, PhD

Professor of Medicine
Chief,
Blood Marrow Transplantation and Cancer Cell Therapy
Stanford University
Stanford, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Incyte Corporation

Target Audience

This program is intended for hematologists and other clinicians involved in the management of with or at risk of GvHD.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review recent advances in our understanding of the underlying pathophysiology of GVHD and ongoing efforts to identify novel biomarkers and prognostic indicators to optimize clinical outcomes
  • Appraise the current and emerging prophylactic strategies for the prevention of GVHD
  • Evaluate available clinical trial data evaluating the use of recently FDA-approved agents and emerging treatment strategies for acute GVHD and chronic GVHD
  • Recognize adverse events and toxicities associated with prophylactic strategies and therapeutic approaches and use this information to develop supportive care plans for patients with GVHD
  • Identify patients at risk of GVHD who are candidates for ongoing clinical trials evaluating emerging options for prophylaxis and management

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey S. Cutler, MD, MPH, FRCPC, has disclosed that he has received consulting fees from Elsalys, Fresenius Kabi, Genentech, Generon, Incyte, Jazz, Kadmon, Medsenic, Omeros, and Pharmacyclics.

Faculty Disclosure

Primary Author

Nelson Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematology Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, North Carolina

Nelson Chao, MD, MBA, has disclosed that he has received fees for non-CME/CE services from Fate, Takeda, and ViaCyte.

David Miklos, MD, PhD

Professor of Medicine
Chief,
Blood Marrow Transplantation and Cancer Cell Therapy
Stanford University
Stanford, California

David Miklos, MD, PhD, has disclosed that he has received funds for research support from Adaptive, Becton Dickinson, Genentech, IsoPlexis, Kite/Gilead Sciences, Novartis, and Pharmacyclics and fees for non-CME/CE services from Adaptive, AlloGene, Janssen, Juno/Celgene/Bristol-Myers Squibb, Kite/Gilead Sciences, Miltenyi, Novartis, Pharmacyclics, and Precision Bioscience.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 08, 2020, through December 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners in treating patients with hematologic malignancies with or at risk of GvHD.